A new trading day began on Monday, with Nurix Therapeutics Inc (NASDAQ: NRIX) stock price up 4.26%% from the previous day of trading, before settling in for the closing price of $11.49. NRIX’s price has ranged from $8.18 to $29.56 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company slipped by -38.86% over the past five years. Meanwhile, its annual earnings per share averaged -2.61%. With a float of $74.71 million, this company’s outstanding shares have now reached $76.23 million.
Let’s look at the performance matrix of the company that is accounted for 286 employees. In terms of profitability, gross margin is 78.08%, operating margin of -408.87%, and the pretax margin is -369.08%.
Nurix Therapeutics Inc (NRIX) Insider Updates
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Nurix Therapeutics Inc is 2.00%, while institutional ownership is 110.63%. The most recent insider transaction that took place on May 02 ’25, was worth 70,243. In this transaction Chief Financial Officer of this company sold 6,198 shares at a rate of $11.33, taking the stock ownership to the 33,724 shares. Before that another transaction happened on May 02 ’25, when Company’s Officer proposed sale 6,198 for $11.16, making the entire transaction worth $69,170.
Nurix Therapeutics Inc (NRIX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.8 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -2.61% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -1.52% during the next five years compared to -38.86% drop over the previous five years of trading.
Nurix Therapeutics Inc (NASDAQ: NRIX) Trading Performance Indicators
Here are Nurix Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 6.26. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 16.19.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.81, a number that is poised to hit -0.71 in the next quarter and is forecasted to reach -3.21 in one year’s time.
Technical Analysis of Nurix Therapeutics Inc (NRIX)
Nurix Therapeutics Inc (NASDAQ: NRIX) saw its 5-day average volume 0.71 million, a negative change from its year-to-date volume of 0.88 million. As of the previous 9 days, the stock’s Stochastic %D was 24.62%.
During the past 100 days, Nurix Therapeutics Inc’s (NRIX) raw stochastic average was set at 30.77%, which indicates a significant decrease from 40.64% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.26% in the past 14 days, which was lower than the 69.61% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $10.82, while its 200-day Moving Average is $17.70. Nevertheless, the first resistance level for the watch stands at $12.21 in the near term. At $12.44, the stock is likely to face the second major resistance level. The third major resistance level sits at $12.89. If the price goes on to break the first support level at $11.53, it is likely to go to the next support level at $11.08. Assuming the price breaks the second support level, the third support level stands at $10.85.
Nurix Therapeutics Inc (NASDAQ: NRIX) Key Stats
With a market capitalization of 913.31 million, the company has a total of 76,236K Shares Outstanding. Currently, annual sales are 54,550 K while annual income is -193,570 K. The company’s previous quarter sales were 18,450 K while its latest quarter income was -56,350 K.
